



REGENERATIVE MEDICINE

CAPABILITIES BRIEF

Eagle Health Analytics, LLC (EHA) is a certified 8(a) Alaska Native Corporation (ANC) that contracts with federal agencies and military partners through both the direct award and competitive procurement processes. We work with experts in regenerative medicine to circumvent the immune responses associated with conventional medical technology by using the patient's own cells rather than artificial or natural materials that are unfamiliar to the body. EHA's developments in this field revolutionize the use of stem cells to restore healthy organ and tissue function; this therapy represents one of the most promising areas for the next generation of groundbreaking treatments.

As a small business, EHA is singularly qualified to support federal programs in spheres where previously only large companies have been players. Our 8(a) status allows EHA to accept direct awards (sole-source contracts) up to \$22 million. Awards to an 8(a) ANC cannot be protested.

EHA ATLANTA OFFICE

2835 Brandywine Rd.
Suite 200
Atlanta, GA 30341

EHA CORPORATE OFFICE

1826 N Loop 1604 W
Suite 336F
San Antonio, TX 78248

EAGLE HEALTH ANALYTICS

SBA Certified 8(a) Contractor
Primary NAICS: 541715
EHA DUNS: 081341367
EHA Cage Code: 85TV8

SBA CONTACT

Please [contact us](#) directly for information on our SBA Officer.

MILITARY REGMED SUPPORT

EHA provides senior scientists and biomedical engineers to lead Trauma and Clinical Care Research (TCCR) for the U.S. Air Force Trauma and Resuscitation Research Program (AFT2R). EHA also manages animal and live tissue studies in the fields of hemorrhage, resuscitation, endovascular technologies, extra-corporeal life support, and molecular biology. Our work in this program leads to novel treatments that can greatly enhance the generation of new tissue needed for wounds sustained in battlefield combat.

STEM CELL TECHNOLOGY ADVOCACY

EHA is a proud supporter of regenerative medicine and ethical stem cell research through our membership in the Genetics Policy Institute and Regenerative Medicine Foundation. Additionally, EHA has been a proud sponsor of the World Stem Cell Summit since 2014.

The REGROW Act modernizes FDA's current regulatory approach toward safe and effective cell therapies, while protecting approval pathways under sections 351 and 361 of the Public Health Service Act. The REGROW Act also aligns with recommendations included in Bipartisan Policy Center's recent report entitled

Advancing Regenerative Cellular Therapy:
Medical Innovation for Healthier Americans.

STEM CELL INDUSTRY COLLABORATION

EHA has partnered with SYNIVIVO, a CFD Research Corporation Life Science company located within the Hudson Alpha Institute for Biotechnology, in a DoD funded project to further develop CFDR's Integrated Stem Cell Impedance Analyzer (iSCIA). This novel medical diagnostic device can directly detect the differentiation state of a mixed population of stem cells in a non-invasive manner and provide a purified stream of differentiated cells that can then be used therapeutically in a clinical setting at a higher yield and lower cost.

PARTNERS

- U.S. Air Force Trauma and Resuscitation Research Program (AFT2R)
- Department of Defense (DoD)
- Centers for Disease Control and Prevention (CDC)
- Genetics Policy Institute
- Regenerative Medicine Foundation
- World Stem Cell Summit
- Hudson Alpha Institute for Biotechnology
- SynVivo

The graphic features several hexagonal icons: a DNA double helix, a network of nodes and lines, a group of husky dogs running, a caduceus symbol, and a stylized brain with neural connections. A large black circle is positioned in the center, containing the text 'VISIT US' and the website 'ehealthanalytics.com'. To the right, a large blue circle contains the text 'CONTACT US' followed by contact information for James M. Watt, PhD.

VISIT US
ehealthanalytics.com

CONTACT US
James M. Watt, PhD
VP for Life Sciences
Atlanta, GA
205.213.0967
james.watt@ehealthanalytics.com